Aicaigou LogoB2B Wiki

Nanoformulation

Updated: 2026-09-15

Overview

Nanoformulation represents a cutting-edge approach in pharmaceuticals where active ingredients are engineered into nanostructures (1-1000 nm) to overcome biological barriers. These formulations leverage unique nanoscale phenomena to improve drug solubility, extend circulation time, and enable tissue-specific targeting. Common types include liposomes, polymeric nanoparticles, and inorganic nanocarriers. The technology is particularly transformative for poorly soluble drugs and biologics, with over 50 FDA-approved nanoformulations currently in clinical use.

Physical and Chemical Properties

Nanoformulations exhibit distinct properties from bulk materials due to high surface-area-to-volume ratios. Particle size typically ranges 10-200 nm for intravenous delivery, with zeta potentials between ±30 mV ensuring colloidal stability. Critical quality attributes include polydispersity index (<0.3 ideal), drug loading capacity (often 5-20% w/w), and in vitro release profiles. Advanced characterization requires dynamic light scattering, electron microscopy, and HPLC assays for quantification.

Main Applications

Oncology dominates nanoformulation use, with paclitaxel albumin-bound nanoparticles (Abraxane®) showing 33% higher tumor accumulation than conventional drugs. Vaccine development utilizes lipid nanoparticles for mRNA delivery, as demonstrated by COVID-19 vaccines. Emerging applications include crossing the blood-brain barrier for neurodegenerative diseases and ocular delivery where traditional formulations fail. Over 40% of pipeline nanodrugs target chronic inflammatory conditions.

Safety and Storage

Sterile manufacturing under ISO Class 5 conditions is mandatory for injectable nanoformulations. Stability studies must monitor particle aggregation, drug leakage, and preservative efficacy over shelf life (typically 12-24 months at 2-8°C). Occupational safety requires NIOSH-approved respirators for dry nanopowders. Environmental risk assessments should address potential bioaccumulation, with proper disposal through incineration or chemical neutralization.

B2B Procurement Guide

For research quantities, prioritize vendors providing full analytical certificates (COA) with HPLC purity >98% and endotoxin levels <5 EU/mg. GMP manufacturing partners should demonstrate successful FDA/EMA filings. Bulk procurement contracts should specify: 1) Particle size tolerances (±10% of target), 2) Residual solvent limits (ICH Q3C compliance), 3) Stability data under shipping conditions (-20°C to +40°C for 72h testing).

Related Manufacturers